Cancer stem cells and angiogenesis

Seminars in Cancer Biology

Volumn 19, Issue 5, 2009, Pages 279-284

  Bjerkvig, Rolf ^a,b   Johansson, Mikael ^b,c   Miletic, Hrvoje ^a   Niclou, Simone P ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Cancer stem cells; Energy metabolism; Glycolysis; Tumor progression

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; BCR ABL PROTEIN; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; GLUCOSE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NESTIN; ONCOPROTEIN; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PYRUVIC ACID; RAS PROTEIN; VANDETANIB;

ADAPTATION; ANAEROBIC METABOLISM; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; CELL DIVISION; CELL FUNCTION; CELL HYPOXIA; CELL METABOLISM; CELL MIGRATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODEL; DRUG TARGETING; EPIGENETICS; GENE MUTATION; GENETIC REGULATION; GLIOMA; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; REVIEW; STEM CELL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION;

HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 70549096071     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.09.001     Document Type: Review

References (69)

1. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 (1976) 23-28
2. Cohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40 (1867) 1-79
3. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memor Observ Chir Pract 11 (1874) 217-226
4. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
5. Tysnes B.B., and Bjerkvig R. Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta 1775 (2007) 283-297
6. Cahill D.P., Kinzler K.W., Vogelstein B., and Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9 (1999) M57-60
7. Frank S.A., and Nowak M.A. Problems of somatic mutation and cancer. Bioessays 26 (2004) 291-299
8. Armitage P., and Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8 (1954) 1-12
9. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
10. Renan M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7 (1993) 139-146
11. Pardal R., Clarke M.F., and Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3 (2003) 895-902
12. Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., and Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89 (1997) 3104-3112
13. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
14. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 105 (2005) 2733-2740
15. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
16. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003) 3983-3988
17. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64 (2004) 7011-7021
18. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
19. Gibbs C.P., Kukekov V.G., Reith J.D., Tchigrinova O., Suslov O.N., Scott E.W., et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7 (2005) 967-976
20. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
21. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., et al. tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65 (2005) 9328-9337
22. Collins A.T., Berry P.A., Hyde C., Stower M.J., and Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65 (2005) 10946-10951
23. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., and Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5 (2005) 899-904
24. Perez-Losada J., and Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer 3 (2003) 434-443
25. Jordan C.T. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol 16 (2004) 708-712
26. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., et al. Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67 (2007) 4010-4015
27. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., and Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17 (2003) 3029-3035
28. Jamieson C.H., Weissman I.L., and Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell 6 (2004) 531-533
29. Passegue E., Jamieson C.H., Ailles L.E., and Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci USA 100 Suppl. 1 (2003) 11842-11849
30. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122 (2008) 761-768
31. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., and Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 456 (2008) 593-598
32. Hill R.P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 66 (2006) 1891-1895 [discussion 0]
33. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., and Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science (2007) 317-337
34. Odoux C., Fohrer H., Hoppo T., Guzik L., Stolz D.B., Lewis D.W., et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68 (2008) 6932-6941
35. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift 1924; 152:319-44.
36. Warburg O, Wind E, Negelein E. On the metabolism of tumours in the body. In: The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlen, London: Constable&Co., Ltd; 1930
37. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
38. He X., Brenchley P.E., Jayson G.C., Hampson L., Davies J., and Hampson I.N. Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res 64 (2004) 3928-3933
39. Postovit L.M., Adams M.A., Lash G.E., Heaton J.P., and Graham C.H. Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J Biol Chem 277 (2002) 35730-35737
40. Postovit L.M., Adams M.A., Lash G.E., Heaton J.P., and Graham C.H. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 108 (2004) 47-53
41. Cipolleschi M.G., Dello Sbarba P., and Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 82 (1993) 2031-2037
42. Kubota Y., Takubo K., and Suda T. Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche. Biochem Biophys Res Commun 9 (2008) 335-366
43. Vlaski M., Lafarge X., Chevaleyre J., Duchez P., Boiron J.M., and Ivanovic Z. Low oxygen concentration as a general physiologic regulator of erythropoiesis beyond the EPO-related downstream tuning and a tool for the optimization of red blood cell production ex vivo. Exp Hematol 37 (2009) 573-584
44. Ito K., Hirao A., Arai F., Takubo K., Matsuoka S., Miyamoto K., et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12 (2006) 446-451
45. Palmer T.D., Schwartz P.H., Taupin P., Kaspar B., Stein S.A., and Gage F.H. Cell culture. progenitor cells from human brain after death. Nature 411 (2001) 42-43
46. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S., and Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26 (2008) 1818-1830
47. Kendall S.E., Najbauer J., Johnston H.F., Metz M.Z., Li S., Bowers M., et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells 26 (2008) 1575-1586
48. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4 (2009) 226-235
49. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1 (2007) 101-112
50. Parmar K., Mauch P., Vergilio J.A., Sackstein R., and Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104 (2007) 5431-5436
51. Iwasaki H., and Suda T. Cancer stem cells and their niche. Cancer Sci 100 (2009) 1166-1172
52. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
53. Robey R.B., and Hay N. Is Akt the "Warburg kinase"? Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19 (2009) 25-31
54. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
55. Nogueira V., Park Y., Chen C.C., Xu P.Z., Chen M.L., Tonic I., et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14 (2008) 458-470
56. Folkman J. Tumor angiogenesis. Adv Cancer Res 43 (1985) 175-203
57. Folkman J. Toward an understanding of angiogenesis: search and discovery. Perspect Biol Med 29 (1985) 10-36
58. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
59. Hillen F., and Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26 (2007) 489-502
60. Leenders W.P., Kusters B., Verrijp K., Maass C., Wesseling P., Heerschap A., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10 (2004) 6222-6230
61. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 62 (2002) 4645-4655
62. Dickson P.V., Hamner J.B., Sims T.L., Fraga C.H., Ng C.Y., Rajasekeran S., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950
63. Zuniga R.M., Torcuator R., Jain R., Anderson J., Doyle T., Ellika S., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91 (2009) 329-336
64. Sakariassen P.O., Prestegarden L., Wang J., Skaftnesmo K.O., Mahesparan R., Molthoff C., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103 (2006) 16466-16471
65. Thorsen F., Jirak D., Wang J., Sykova E., Bjerkvig R., Enger P.O., et al. Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR Biomed 21 (2008) 830-838
66. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11 (2007) 69-82
67. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 (2009) 740-745
68. Nghiemphu P.L., Liu W., Lee Y., Than T., Graham C., Lai A., et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72 (2009) 1217-1222
69. Shahrzad S., Bertrand K., Minhas K., and Coomber B.L. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2 (2007) 119-125